Patients Are Left With Few Options as GLP-1 Copycats Disappear

Michael Futter was desperate to lose weight. In February 2022, the 46-year-old from New Jersey had prediabetes and high blood pressure when his doctor asked if he had considered trying a GLP-1 medication. She prescribed him Wegovy, the blockbuster anti-obesity drug made by Novo Nordisk.

At the time, Futter’s health insurance plan covered the drug, which costs $1,350 a month. He was only on the hook for a $25 copay. But when he changed jobs, none of the plans offered by his new employer covered Wegovy. He was crushed. He was losing weight fast and felt better than he had in years. He turned

Related News

How to Overcome Imposter Syndrome and Launch Your First Product with Confidence

Intel was on the brink of downfall. A twist in the AI race could boost its revival

Incident involving suspect with a knife closes Hwy. 101 in San Jose

Scott Pelley speaks: ‘CBS News is on fire’ and Bari Weiss should be removed

5 vehicles stolen from Alameda County parking garage in Oakland

Video footage shows large groups of people fighting in Oakland